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Abstract 
Recently, we reported that curcumin (diferuloylmethane) inhibits the growth of several different kinds of tumor cells. In order to investigate the 
mechanism of this inhibition, we examined the effects of curcumin on different protein kinases: highly purified protein kinase A (PkA), protein kinase 
C (PkC), protamine kinase (cPK), phosphorylase kinase (PhK), autophosphorylation-activated protein kinase (AK) and pp60”“” tyrosine kinase. 
While all kinases tested were inhibited by curcumin, only PhK was completely inhibited at relatively lower concentrations. At around 0.1 mM 
curcumin, PhK, pp60”““, PkC, PkA, AK, and cPK were inhibited by 98%, 40%, 15%, lo%, l%, and 0.5%, respectively. Lineweaver-Burk plot analysis 
indicated that curcumin is a non-competitive inhibitor of PhK with a Ki of 0.075 mM. Overall, our results indicate that curcumin is a potent and 
selective inhibitor of phosphorylase kinase, a key regulatory enzyme involved in the metabolism of glycogen. This has important implications for 
the anti-proliferative ffects of curcumin. 
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1. Introduction 
Curcumin (diferuloylmethane) is a major active com- 
ponent of the food flavor, turmeric (Curcuma longa). 
The anti-carcinogenic properties of curcumin in animals 
has been demonstrated by its inhibition of both tumor 
initiation induced by benz[a]pyrene and 7,12 dimeth- 
ylbenz[a]anthracene [l-4] and tumor promotion induced 
by phorbol esters [5,6]. Besides its anti-carcinogenic ef- 
fects, curcumin exhibits anti-inflammatory properties in 
vivo [7-91. The pharmacological safety of curcumin is 
demonstrated by its consumption for centuries of up to 
100 mg/day by people in certain countries [7]. 
In vitro, curcumin inhibits neutrophil activation, sup- 
presses mitogen-induced proliferation of blood mononu- 
clear cells, inhibits mixed lymphocyte reaction and inhib- 
its proliferation of smooth muscle cells [lO,l 11. Cur- 
cumin is also a potent scavenger of reactive oxygen spe- 
cies, protects hemoglobin from nitrite-induced oxidation 
to methemoglobin, and inhibits lipid peroxidation [12- 
141. Some of these activities are also responsible for its 
ability to protect DNA from free radical-induced dam- 
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age and to protect hepatocytes against various toxins 
[14,15]. 
The mechanism underlying these diverse effects of cur- 
cumin is not fully understood. Among the possibilities, 
it has been shown that the phorbol ester-induced tran- 
scriptional factor c_junlAP-1, are suppressed by cur- 
cumin [16]. Recently, curcumin has been shown to be 
highly effective in inhibiting type 1 human immunodefi- 
ciency virus long terminal repeat-directed gene expres- 
sion and virus replication [ 171. We have recently reported 
that curcumin inhibits the growth of a wide variety of 
tumor cells (Gupta and Aggarwal, submitted). In an at- 
tempt to investigate the mechanism of action of cur- 
cumin, we examined its effect on the activities of various 
protein kinases. The results presented in this report indi- 
cate that, among the kinases tested, curcumin is a selec- 
tive and non-competitive inhibitor of phosphorylase ki- 
nase. 
2. Materials and methods 
Cytosolic protamine kinase and autophosphorylation-activated pro- 
tein kinase were a generous gift from Dr. Z. Damuni, Department of 
Biological Sciences, Unviersity of South Carolina, Columbia, SC. 
These protein kinase preparations were judged to be homogeneous 
based on SDS-PAGE and gel nermeation chromatonrauhv. Phosuhorv- 
lase kinase (PhK) (170 v/m&, phosphorylase b, catalytic subunit of 
protein kinase A (41 Ulmg), histone H-l and H-2B, protamine sulfate 
(salmine), myelin basic protein, curcumin, polyglutamic acid-tyrosine 
(41) and phosphatidyl-L-serine were from Sigma Chemical Co. Protein 
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kinase C (PkC) (1,200 U/mg) was from Calbiochem Corp. [Y-~‘P]ATP 
was obtained from ICN Biomedicals Inc. pp60”~“‘” (40 U/mg) was a 
generous gift from Dr. Raymond Budde of the M.D. Anderson Cancer 
Center, Houston, TX. 
2.1. Protein kinase assays 
Protein kinase A (PkA), PkC, and cytosolic protamine kinase (cPK) 
were assayed as described previously 1181 with some modifications. 
Briefly, the assays were performed in 0.05 ml mixtures containing 25 
mM Tris-HCl. DH 7.3. 10% elvcerol. 1 mM benzamidine. 14 mM 
p-mercaptoethaAol,O.2 mM ph~~ylme;hyl sulfonyl fluoride, iO0 fig/ml 
leupeptin, 4 PM microcystin, 2 &ml aprotinin, protein kinase, 50 pg 
histone H-l (PkC) or histone H-2B or 1OOpg protamine sulfate, 10 mM 
MgCl*, and 0.2 mM [y-“P]ATP (200-500 cpm/pmol). The reaction was 
initiated by adding MgC& and ATP. After 10 min incubation at 37”C, 
the reaction was terminated by the addition of 1 ml 10% trichloroacetic 
acid (TCA). Protein in the TCA-terminated mixtures was spun into 
pellets by centrifugation for 2 min in a Beckman centrifuge at 
15,000 x g. The pellets were washed five times with TCA. 1 ml scintil- 
lant was added and the radioactivity was counted in a Packard liquid 
scintillation counter. Control tubes were treated in an identical manner 
except that protein kinase was excluded from the mixture. 
PkC was assayed as described above except hat the incubation mix- 
ture also included 0.5 mM CaCl, and 40 fig/ml phosphatidyl-L-serine. 
Phk was assayed as described previously [19], with some modifica- 
tions. The assay mixture contained 25 mM Tris-HCl, pH 7.3, 10% 
glycerol, 1 mM benzamidine, 14 mM/?-mercaptoethanol, 0.2 mM phen- 
ylmethyl sulfonyl fluoride, 100 &ml leupeptin, 4 PM microcystin LR, 
2 ,@ml aprotinin, protein kinase, 50 pg phosphorylase b and 0.5 mM 
CaCI,. Following incubation for 10 min at 37”C, the reaction was 
terminated with 1 ml of 10% TCA and treated as described above. 
The autophosphorylation-activated protein kinase was purified as a 
single polypeptide of apparent M, = 36,000 [20]. Based on substrate 
specificities and chromatographic properties this enzyme was differen- 
tiated from all other known protein kinases. When incubated with ATP, 
AK rapidly undergoes autophosphorylation (t,,Z = 0.5-l min) which 
leads to a lo-fold enhancement in its activity. Both, the auto- 
phosphorylation and activation were reversed by protein phosphatase 
2A. It has also been reported recently that this new kinase phospho- 
rylates and inactivates protein phosphatase 2A and could thus play an 
important role in the regulation of cellular processes by extracellular 
factors. In order to determine the activity of this kinase, it was first 
pre-activated and then assayed with myelin basic protein as substrate 
POI. 
The activity of pp60”+‘” was determined as described previously with 
some modifications [21]. The incubation mixture (0.05 ml) contained 
25 mM Tris-HCl, pH 7.3, 10% glycerol, 1 mM benzamidine, 14 mM 
p-mercaptoethanol, 0.2 mM phenylmethyl sulfphonyl fluoride, 100 bugl 
ml leupeptin, 2 &ml aprotinin,.protein kinise, 5b pg polyglutamic 
acid- tvrosine (4:l). 10 mM M&l, and 0.2 mM Ir-‘*PlATP (200-500 _ I, ” - ., A \ 
cpm/pmol). Following incubation at 37°C for 10 min the mixture was 
blotted onto filter paper and immediately immersed in 10% TCA. The 
paper was then washed with 10% TCA before counting radioactivity 
in the presence of scintillant. 
One unit of protein kinase activity was defined as the amount of 
enzyme that incorporated 1 nmol of phosphoryl groups into substrate/ 
min. To ensure linearity the extent of incorporation of phosphoryl 
groups was limited to < 1 nmol. 
3. Results 
Cm-cumin, or diferuloylmethane (Fig. l), constitutes 
as much as 5% of the food flavor, turmeric (Curcuma 
longa). We examined the effect of different concentra- 
tions of curcumin on the activity of six different protein 
kinases. The result of this experiment (Fig. 2A) indicates 
that curcumin inhibited all the kinases examined but to 
different extents. At around 0.1 mM curcumin, PhK, 
pp60”“‘“, PkC, PkA, AK, and cPK were inhibited by 
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Fig. 1. Structure of curcumin (M, 368). 
98%, 40%, 15%, lo%, l%, and 0.5%, respectively; how- 
ever, higher concentrations of curcumin inhibited 98%, 
95%, 46%, 49%, 17% and 2% of the activity, respectively. 
The inhibitory effect was dose-dependent. Because 
among all the six kinases PhK could be inhibited com- 
pletely by a relatively lesser concentration of curcumin, 
this observation was further investigated in detail. The 
inhibitory effects of curcumin at lower doses on PhK is 
shown in Fig. 2B. Results indicate that the effect of 
curcumin could be noted at as low as 5 PM and it 
plateaued at around 0.3 mM. A reduced activity of PhK 
paralleled with the decrease in the phosphorylation of 
phosphorylase b as analyzed by SDS-PAGE (data not 
shown). The inhibitory effects of curcumin could be 
noted at - 5 ,uM, and no phosphorylated product was 
observed at 1.36 mM. The inhibition kinetics of PhK by 
curcumin was then analyzed by a Lineweaver-Burk plot 
(Fig. 3A) which indicated that curcumin is a non-com- 
petitive inhibitor of PhK. When the slope of each curve 
from Fig. 3A was re-plotted against different concentra- 
tions of curcumin a Ki of 0.075 mM was obtained 
(Fig. 3B). 
4. Discussion 
We report here that curcumin is an inhibitor of several 
different protein kinases. Among the kinases examined, 
only PhK was completely inhibited at relatively low con- 
centrations of curcumin. Previously it was reported that 
curcumin could inhibit cellular PkC [22]. Our results 
indicate that inhibition of PkC by curcumin is only 4& 
50%. Why curcumin inhibits PkC, AK, PkA, and cPK 
only partially, whereas PhK is inhibited completely is not 
clear. Skeletal muscle PhK is a hexadecamer composed 
of four a, b, y, and 6 subunits [19]. The y subunit is 
catalytic and shows significant homology to other pro- 
tein kinases. The CI, /3, and 6 subunits of PhK are regula- 
tory, with 6 being an integral calmodulin subunit. At 
least 90% of the enzyme mass is involved in its regula- 
tion. Therefore, it is possible that curcumin is maximally 
effective against PhK due to its size and multiple regula- 
tory sites. Conformational change in the /I subunit has 
been shown to eliminate the catalytic activity of the y 
subunit completely [23]. Therefore it is possible that cur- 
cumin interacts with the p-subunit, resulting in a change 
in its conformation. Both the CI and j? subunits have been 
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shown to undergo phosphorylation in response to PkA. 
Besides kinase activity, PhK also displays ATPase activ- 
ity [24]. Whether this activity and the autophosphoryla- 
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Fig. 3. (A) Lineweaver-Burk plot analysis of the inhibition of 
phosphorylase kinase by curcumin. The activities of phosphorylase 
kinase (0.03 U) were determined as described in section 2. The incuba- 
tions contained various concentrations of curcumin as indicated. With 
each set of curcumin concentrations, the concentration of phosphory- 
lase b was varied. The other two substrates, viz. MgZ’ and ATP, were 
present at saturating levels (2 mM and 0.2 mM, respectively). The rates 
of each reaction were calculated as pmol of 32P incorporated into 
phosphorylase b per min. The reciprocal values of these velocities are 
plotted against reciprocal concentrations of phosphorylase b as a Line- 
weaver-Burk plot. (B) The slopes of the lines derived from the double 
reciprocal plot are plotted against the relevant concentrations of cur- 
cumin in order to derive the Ki value for curcumin. 
0.003 0.03 0.3 3 
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Fig. 2. (A) Effect of curcumin on the activities of various protein 
kinases. Preparations of PhK (8, 134 U/ml), PkC (0, 6.8 U/ml), PkA 
(*, 5 U/ml), cPK (x, 500 U/ml), AK (A, 500 U/ml) and pp60”-” tyrosine 
kinase (0, 8 U/ml) were assayed with phosphorylase 6, histone H-l, 
histone H-2B, protamine sulfate, myelin basic protein and polyglutamic 
acid-tyrosine as substrates, respectively, as described in section 2 in the 
presence of the indicated concentrations of curcumin. Controls were 
treated in an identical manner except hat dimethylsulfoxide was substi- 
tuted for curcumin. (B) Dose-response of phosphorylase kinase with 
curcumin. Phosphorylase kinase (134 U/ml) was assayed with 
phosphorylase b as described in section 2 in the presence of the indi- 
cated concentrations of curcumin. 
tion activity of PhK are also affected by curcumin is not 
clear at present. 
Near complete inhibition of pp60”“” tyrosine kinase 
was also observed but at much higher concentrations of 
curcumin than that required for the total inhibition of 
phosphorylase kinase. This result could significantly re- 
flect the ability of this compound to inhibit tyrosine 
phosphorylation of proteins and thus form a major part 
of its mechanism of action. Whether curcumin can in- 
hibit the activities of receptor tyrosine kinases as well 
remains to be determined. 
Recently, curcumin has been shown to down-modu- 
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late the expression of the c-junlAP1 gene and also inhibit 
the replication of human immunodeficiency virus [ 16,171. 
Since both of these activities have been shown to be 
kinase-dependent [25-271, it is possible that the effects of 
curcumin in these systems is also due to its effects on 
protein kinases. Because curcumin has been shown to 
inhibit tumor initiation and its promotion by carcino- 
gens [l-6], it is possible that these effects are also medi- 
ated through the inhibition of protein kinases. 
We have shown recently that curcumin could inhibit 
the growth of a wide variety of tumor cells, whereas 
normal cells were found to be relatively resistant (Gupta 
and Aggarwal, submitted). Whether the suppressive f- 
fects of curcumin on tumor cells is due to the inhibition 
of protein kinases described here is not certain. Since 
PhK is a key regulatory enzyme involved in glycogen 
metabolism it is possible that the inhibition of this en- 
zyme may block the autocrine action of growth factors 
needed for cellular proliferation. Kinase inhibitors have 
been shown to display anti-proliferative activity in vitro 
and anti-tumor activity in vivo [28,29]. Because of its 
well-established pharmacological safety in mice and hu- 
mans [7] and its in vitro anti-proliferative activity against 
tumor cells, curcumin may also display in vivo anti- 
tumor activity. 
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